Publish date:

Cramer on the Top 10 Searched Stocks

Temple-Inland and Merck were among the most searched stocks on <I>TheStreet.com</I> Friday; here's what Cramer recently had to say about them.

Stocks ended last week on a strong note with Google (GOOG) - Get Report, Citigroup (C) - Get Report and Caterpillar (CAT) - Get Report leading the way.

The positive momentum from solid earnings reports was greater than most expected, leaving may investors to wonder whether one should take profits or continue to ride this earnings wave into the new week.

With this in mind, we thought it made sense to take the Top 10 Most Searched Stocks on

TheStreet.com

TST Recommends

from the prior trading day and look into

Jim Cramer's most recent take on these stocks

.

These stocks could be in the news for a number of reasons. But it never hurts to hear what Cramer (or any of the other professional investors on the site) has to say about them. The key is to gather as much information as you can in order to make the most informed investment decisions you can.

Let's kick things off with corrugated cardboard maker

Temple-Inland

(TIN)

, a popular stock searched Friday and one that Cramer featured on the

April 7 episode of "Mad Money"

as a stock that's undeservedly lagging its peers.

Cramer believes that Temple-Inland's 3% dividend, makes it the "picture of stability," and he believes its business won't be as affected as most think from weakness in both the economy and housing sectors.

Cramer noted that a weak U.S. dollar makes U.S. cardboard cheaper around the world. The U.S. also has one of the largest uncut softwood forests left, which means Temple-Inland is well positioned for years to come.

Not to be ignored is also the fact that super-investor

Carl Icahn

also owns a 9.8% stake in the company.

Temple-Inland is next scheduled to report quarterly results before the market open on April 29.

Next on the list is

Merck

(MRK) - Get Report

, another stock Cramer says should not be lagging as much as it is against its peers. He featured Merck as a "catch-up" stock on his

April 9 episode of "Mad Money."

Merck shares were hit very hard recently on negative news regarding its anti-cholesterol drug Vytorin, which it co-markets with

Schering-Plough

(SGP)

.

Cramer believes the stock was irrationally sold off and pointed to the fact that Merck saw only modest dips in the prescription rates for Vytorin after the news broke. As we often see, the market can certainly overreact in either direction to positive and negative news.

He believes the Vytorin news is "just a speed bump for Merck," and called the subsequent market cap hit "absurd." But taking all this into account, he believes the earnings estimates are too low and Merck is a discount buy -- his No . 1 pick in the

Dow

.

He also added that the company has a huge buyback program, a 3.5% dividend and is simply too cheap to pass up, especially in a recessionary environment, where drug stocks typically are attractive.

For the rest of Cramer's take on Friday's Top 10 most searched stocks, including

Deere

(DE) - Get Report

and

Qualcomm

(QCOM) - Get Report

,check out

Cramer's Take on Top 10 Most-Searched Stocks from April 18

at Stockpickr.com.

Stockpickr is a wholly owned subsidiary of TheStreet.com.